News
PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback